Personalised medicine for nonsmall cell lung cancer

After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascaux, Céline, Tomasini, Pascale, Greillier, Laurent, Barlesi, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489039/
https://www.ncbi.nlm.nih.gov/pubmed/29141962
http://dx.doi.org/10.1183/16000617.0066-2017
_version_ 1784792793183420416
author Mascaux, Céline
Tomasini, Pascale
Greillier, Laurent
Barlesi, Fabrice
author_facet Mascaux, Céline
Tomasini, Pascale
Greillier, Laurent
Barlesi, Fabrice
author_sort Mascaux, Céline
collection PubMed
description After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer.
format Online
Article
Text
id pubmed-9489039
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-94890392022-11-14 Personalised medicine for nonsmall cell lung cancer Mascaux, Céline Tomasini, Pascale Greillier, Laurent Barlesi, Fabrice Eur Respir Rev Series After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer. European Respiratory Society 2017-11-15 /pmc/articles/PMC9489039/ /pubmed/29141962 http://dx.doi.org/10.1183/16000617.0066-2017 Text en Copyright ©ERS 2017. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Series
Mascaux, Céline
Tomasini, Pascale
Greillier, Laurent
Barlesi, Fabrice
Personalised medicine for nonsmall cell lung cancer
title Personalised medicine for nonsmall cell lung cancer
title_full Personalised medicine for nonsmall cell lung cancer
title_fullStr Personalised medicine for nonsmall cell lung cancer
title_full_unstemmed Personalised medicine for nonsmall cell lung cancer
title_short Personalised medicine for nonsmall cell lung cancer
title_sort personalised medicine for nonsmall cell lung cancer
topic Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489039/
https://www.ncbi.nlm.nih.gov/pubmed/29141962
http://dx.doi.org/10.1183/16000617.0066-2017
work_keys_str_mv AT mascauxceline personalisedmedicinefornonsmallcelllungcancer
AT tomasinipascale personalisedmedicinefornonsmallcelllungcancer
AT greillierlaurent personalisedmedicinefornonsmallcelllungcancer
AT barlesifabrice personalisedmedicinefornonsmallcelllungcancer

Ejemplares similares